Board of Directors
William C. Fioretti was a co-founder of TransGenRx and has been a Director and President of the company since November 2003. He became Chief Executive Officer of the company in July 2004. Mr. Fioretti also has been Chief Executive Officer and Chairman of the Board of Agritech Technologies Ltd. since 1991 and Chairman of the Board of NanoMatrix Inc. since 2001; each of such companies is a privately owned biotech company. Mr. Fioretti was a founder of Mannatech™ Incorporated, a publicly traded nutritional supplement company, and served as its Chief Executive Officer and Chief Science Officer from 1994 to 1998. Mr. Fioretti received a Bachelor of Science (cum laude) from Appalachian State University in 1974; he did graduate work in biochemistry at the Medical University of South Carolina from 1974 to 1978 and engaged in postgraduate studies at the University of Florida from 1978 to 1980.
Dr. Richard C. Cooper has been Executive Vice President – Research and Development of TransGenRx since November 2003 and a Director of the company since 2001. Since 1991, Dr. Cooper has been a Professor at Louisiana State University, where he holds a joint appointment to the LSU Agricultural Center (LSU AgCenter) and the LSU School of Veterinary Medicine. Dr. Cooper received a Bachelor of Science degree from Mississippi College in 1985, a Master of Science degree from Mississippi State University in 1988 and a Ph.D. from the University of Georgia in 1991. His research has focused on DNA delivery and protein expression in transgenic animals and applications cell culture for the purpose of pharmaceutical protein expression. Dr. Cooper has eight issued patents and 15 pending applications on stable DNA integration, transgenic animal production and protein expression.
John Gallagher has been a Director of TransGenRx since September 2004, Secretary of the company since August 2005 and the company’s Corporate Counsel since November 2005. Mr. Gallagher, an attorney, has served since 2002 as general counsel to Genendo Pharmaceutical, N.V., a company engaged in the business of buying and selling pharmaceuticals in the international market. From 1997 to 2001, Mr. Gallagher served as Co-Chairman and Co-President of European Micro Holdings, Inc., a publicly traded distributor of microcomputer products. Mr. Gallagher received a Bachelor of Arts degree in 1976 and a Juris Doctorate degree in 1978 from the University of Florida.
Robert J. Kenney, MD, has been on the Board of Directors of TransGenRx since May 2009. Dr. Kenney obtained his undergraduate degree at the University of Southwestern Louisiana and his Doctor of Medicine degree from Tulane School of Medicine in 1980. Thereafter, he completed his Internship and Residency in Internal Medicine and Fellowship in Nephrology at the University of Texas Health Science Center at Dallas. He is a diplomat of the American Board of Internal Medicine and the subspecialty of Nephrology. Since 1985, he has been a practicing physician in the Baton Rouge area. Currently, he is the Senior Partner in Renal Associates of Baton Rouge, LLC, a large private practice nephrology group. He holds memberships in several specialty societies and remains active at the national level with the Renal Physicians Association. Since 1997, he has been a member of the Institutional Review Board for Human Research at Louisiana State University in Baton Rouge. He participates in the Medical Director Advisory Committees both at the Division and Corporate levels for Fresenius Medical Care – North America, the largest dialysis company in the world. He is the author of several publications and presentations, some dealing with disaster responsiveness in the dialysis community. As a result, he was named a co-team leader in the Kidney Community Emergency Response coalition, a national organization sponsored by the Center for Medicare and Medicaid Services.
|
